NULOJIX (belatacept), selective immunosuppressant

Maintenance of minor clinical added value in prophylaxis of graft rejection in renal transplant in non-immunised patients with an immunological status positive for Epstein-Barr virus.

• NULOJIX, in combination with corticosteroids and mycophenolic acid (MPA), has Marketing Authorisation for prophylaxis of graft rejection in adults receiving a renal transplant.
• New data have confirmed reduced impairment of renal function with belatacept relative to ciclosporin at 7 years. However, there are less nephrotoxic alternatives and there is still an increased risk of acute rejection with belatacept relative to ciclosporin.
• The available data do not permit differentiating between belatacept and tacrolimus in terms of efficacy and safety.